Tuatara Capital

Tuatara Capital

A venture capital and private equity firm investing in the legal cannabis industry.

Tuatara Capital is a venture capital and private equity firm investing in the legal cannabis industry that is headquartered in New York City, New York and was founded in 2014 by mark Zittman, Al Foreman, and Marc Riiska. According to the company's LinkedIn page (as of November 2019), Tuatara Capital is managing more than $330 million in assets related to the cannabis industry.

Investments

Tuatara Capital focuses in investing in several sectors of the legal cannabis industry which include: research & testing, cultivation, processing, consumer & retail, technology, and industrial services. Notable investments made by Tuatara Capital include: GCH, Teewinot Life Sciences, Green dot labs, Slang Worldwide, Inc., The CanAscen Group, Enlighten, Connecticut Pharmaceutical Solutions, Sumpaz Enterprises, CannaKids, Green Flower Media, Willow Biosciences, Demetrix, and Hana.

Investment funds

Fund I

On March 21, 2016 Tuatara Capital raised $37 million for their first venture capital fund dedicated to investing in the cannabis industry.

Fund II

On May 16, 2019 Tuatara Capital announced raising more than $206 million for their second venture capital fund.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Teewinot Life Science

Pharmaceutical company that manufactures and licenses technology to make cannabinoid based therapies.

Demetrix is a biotechnology company that uses genes found in natural medicines and introduces them to domesticated microbes, for example, the synthetic production of certain chemicals. Demetrix was founded by Dr Haseltine and Jay Keasling.

2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.